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Abstract
Sarcomas are heterogeneous and clinically challenging soft tissue
and bone cancers. Although constituting only 1% of all human
malignancies, sarcomas represent the second most common type of
solid tumors in children and adolescents and comprise an important
group of secondary malignancies. More than 100 histological
subtypes have been characterized to date, and many more are being
discovered due to molecular profiling. Owing to their mostly aggres-
sive biological behavior, relative rarity, and occurrence at virtually
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every anatomical site, many sarcoma subtypes are in particular dif-
ficult-to-treat categories. Current multimodal treatment concepts
combine surgery, polychemotherapy (with/without local hyperther-
mia), irradiation, immunotherapy, and/or targeted therapeutics.
Recent scientific advancements have enabled a more precise molec-
ular characterization of sarcoma subtypes and revealed novel thera-
peutic targets and prognostic/predictive biomarkers. This review
aims at providing a comprehensive overview of the latest advances
in the molecular biology of sarcomas and their effects on clinical
oncology; it is meant for a broad readership ranging from novices to
experts in the field of sarcoma.
Keywords bone sarcoma; molecular diagnostics; molecular medicine; soft
tissue sarcoma; targeted therapy
Subject Categories Cancer; Molecular Biology of Disease; Musculoskeletal
System
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See the Glossary for abbreviations used in this article.
Epidemiology of sarcoma
Although sarcomas are rare among adult malignancies, they repre-
sent 12–15% of all pediatric tumors (Stiller et al, 2013). Despite the
implementation and continuous optimization of multimodal thera-
pies, around one-third of sarcoma patients still succumb to the
disease. Historically, sarcomas have been clustered in two large
subgroups, according to the anatomical site of occurrence—sarcomas
of the skeleton and sarcomas of the soft tissues (hereafter referred
to as “bone sarcomas” or “soft tissue sarcomas” [STSs], respec-
tively). Both subgroups comprise a variety of histological subtypes,
and recent technological advances have enabled to decipher a
constantly increasing number of subtypes at the molecular level
(Fig 1; Baldauf et al, 2018a; Koelsche et al, 2018a; Watson et al,
2018; Weidema et al, 2020). Table 1 summarizes the major sarcoma
subtypes discussed in this review and their main features.
Among bone sarcomas, osteosarcoma (OS) is the most frequent
subtype (Heymann, 2014). OS primarily affects adolescents and
young adults, with the first and largest peak of incidence at age ~10–
14 years. Coinciding with the pubertal growth spurt, the incidence
rate of OS is 4 (3.5–4.6) for the range 0–14 years and 5 (4.6–5.6) for
the range of 0–19 years per year per million persons (Ottaviani &
Jaffe, 2009). The current standard of care was first introduced in the
late 1970s and remains largely unaltered despite numerous efforts to
improve outcomes (Rosen et al, 1976). Nowadays, patients with
localized disease still face 5-year overall survival rates < 70%, and
< 20% of patients who develop metastatic disease or relapse survive
> 3 years (Roberts et al, 2019). Ewing sarcoma (EwS) is included in
the group of bone sarcomas because it is an aggressive sarcoma of
both bone (~85% of cases) and soft tissue (~15% of cases), and
because it has an incidence and survival rate similar to OS.
The STS subgroup comprises ~70–80% of all sarcomas with > 70
heterogenous histological subtypes (WHO Classification of
Tumours: Soft Tissue and Bone Tumours, 2020). Although STSs
represent < 1% of all cancers, they have the highest incidence
among rare malignancies. Overall, the 5-year survival for STS is esti-
mated at ~57–62% and can vary widely depending on the disease
stage and the complex interplay between anatomical site and STS
subtype (Lyu et al, 2019). Unfortunately, the epidemiological data
Glossary
Cancer stem cells
(CSCs)
Cells within the tumor found in very small
fractions that are thought to be responsible
for resistance to cancer treatments and thus
relapse.
Cell dormancy Stage in cancer progression during which
tumor cells cease dividing but survive in a
quiescent state while waiting for appropriate
environmental conditions.
Chorioallantoic
Membrane (CAM)
models
Chick embryo CAM models used to study
tumor formation, angiogenesis, and
metastasis.
Circulating tumor
cells (CTCs)
Cells that leak into the vasculature or
lymphatics from a primary tumor and are
carried around the body in the blood
circulation.
Epigenomic
alterations
Heritable change that does not affect the
DNA sequence but results in a change in
gene expression.
Extracellular vesicles
(EVs)
Heterogeneous family of vesicles generated
from different subcellular compartments and
released into the extracellular space or the
blood circulation.
Genomic alterations Permanent modifications in the DNA
sequence including somatic mutations, copy-
number variations (CNVs), and gene fusions.
Immunotherapy Type of cancer treatment that aids the
immune system to fight tumors.
Oncolytic viruses Viruses that, by their intrinsic properties or
through genetic engineering, specifically
replicate in and kill cancer cells.
Orthotopic
xenografts
Animal models based on the injection of
tumor cell lines in the location where the
tumors typically appear in humans.
Patient-derived
xenografts (PDXs)
Animal model based on transplantation of
human tumor biopsies that encompass tumor
cells and the TME in immunodeficient
animals.
Pediatric tumors Tumors that typically arise between 0–14
years of age.
Precision medicine Approach to patient care that allows
physicians to select the treatments that are
most likely to help patients based on a
molecular understanding of their disease.
Sarcomas Malignant neoplasms that originate from the
skeleton or soft tissues.
Tumor
microenvironment
(TME)
Cellular environment in which cancer cells
reside encompassing the extracellular matrix
and stromal cells (endothelial cells,
fibroblasts, and immune cells)
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on specific STS subtypes are limited and frequently incomplete.
National initiatives are ongoing to improve the databases, and they
likely will benefit from the use of “big data” approaches. A recent
review on the epidemiology of STSs in Italy and other European
countries stated that they generally have an incidence of 6.27 and
4.71 cases per 100,000 inhabitants per year in Italy and Europe,
respectively (Trama et al, 2019), with median ages at diagnosis of 58
and 63 years, respectively. Leiomyosarcoma (LMS), liposarcoma
(LPS), and undifferentiated pleomorphic sarcoma (UPS; previously
termed malignant fibrous histiocytoma) are the most common STS
subtypes (WHO Classification of Tumours: Soft Tissue and Bone
Tumours, 2020). A recent study in the Australian population reported
that the incidence rate has almost doubled in the last 30 years
(Bessen et al, 2019), which could be related to improved diagnostics
or molecular pathology sub-classification.
The complex biology of sarcoma: How current knowledge
may affect therapy
To date, targeted therapy of sarcomas has only been partially effec-
tive, possibly due to the existence of compensatory pathways, the
intrinsically heterogeneous nature of sarcomas, and the complex
interplay with the tumor microenvironment (TME; Brown et al,
2018). In the TME, multiple intermingled cell types coexist through
complex heterotypic cellular interactions and communicate via a
large array of paracrine signals. The heterogeneity of different
cancer cell subpopulations is further modulated by the extracellular
matrix, admixed with intra- and extracellular reactive elements,
such as metabolites, oxygen tension, and pH.
Impact of the tumor microenvironment on the stemness and
behavior of sarcoma cells
Similar to the “seed and soil” theory described for other malignan-
cies, sarcoma cells evolve in a permissive milieu favoring their
quiescence and drug resistance or their proliferation and aggressive-
ness. Sarcoma cells are embedded in a highly heterogeneous tissue
context composed of immune cells, endothelial cells, pericytes,
mesenchymal stem cells (MSCs), cancer-associated fibroblasts
(CAFs), and nerve fibers, all of which may influence their behavior
and favor “stemness” properties. Cancer stem cells (CSCs) usually
represent only a very small fraction of the tumor cell mass, yet their
eradication is critical for improving drug response. Indeed, CSCs
have a great potential for self-renewal and develop protective mech-
anisms against conventional anti-tumor treatments, thereby causing
sarcoma relapse and metastasis (Abarrategi et al, 2016; Brown et al,
2017a; Fourneaux et al, 2019; Hatina et al, 2019). Common meth-
ods of isolating/enriching CSCs to model sarcoma heterogeneity
in vitro include culturing floating three-dimensional (3D)-colonies
(tumorspheres), cell sorting based on the expression of specific
markers (i.e., CD133, ABCG2, CD44, CD184, STRO1, CD117, CD271,
or aldehyde dehydrogenase 1), the ability to extrude fluorescent
dyes (side populations), or the selective pressure induced by long-
term culturing with chemotherapeutic drugs. CSCs have been
extensively characterized in both bone sarcomas and STSs (Salerno
et al, 2013; Abarrategi et al, 2016; Brown et al, 2018; Genadry et al,
2018; Skoda & Veselska, 2018; Hatina et al, 2019; Schiavone et al,
2019; Fig 2).
Stemness in sarcoma is a fluctuating functional state orchestrated
by the expression of pluripotency factors, such as OCT3/4, NANOG,
KLF4, and, especially, SOX2 (Basu-Roy et al, 2012; Maurizi et al,
 1 Angiosarcoma
 2 Alveolar soft part sarcoma (ASPS)
 3 Chordoma
 4 Liposarcoma (LPS; dediff.)
 5 Dermatofibrosarcoma protuberans
 6 Ewing sarcoma (EwS)
 7 Gastrointestinal stromal tumor (GIST)
 8 Kaposi sarcoma
 9 Fibromyxoid sarcoma (low-grade)
 10 Leiomyosarcoma (LMS)
 11 Liposarcoma (LPS; myxoid)
 12 Malignant peripheral nerve sheath tumor (MNPST)
 13 Osteosarcoma (OS; high-grade)
 14 Alveolar rhabdomyosarcoma (ARMS)
 15 Embryonal rhabdomyosarcoma (ERMS)
 16 Solitary fibrous tumor (SFT)
 17 Synovial sarcoma (SS)
 18 Undifferentiated pleomorphic sarcoma (UPS)
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Figure 1. Diversity of sarcomas as highlighted by DNA methylation profiling.
t-distributed stochastic neighbor embedding (t-SNE) plot of n = 18 major sarcoma and soft tissue tumor subtypes based on genome-wide DNA methylation profiling on
Illumina EPIC arrays (Koelsche et al, 2018a,b). Web-link to classifier: www.molecularsarcomapathology.org.
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2018; Skoda & Veselska, 2018; Sannino et al, 2019). The expression
of these factors in sarcomas is oncogene-driven and triggered by a
combination of mutational and epigenetic events or by developmen-
tal programs (Rodriguez et al, 2012; Xiao et al, 2013). These events
ultimately result in the deregulation of pathways that control stem-
ness and differentiation, such as Hedgehog, Notch, Wnt/b-Catenin,
Hippo, or ALK (Graf Finckenstein et al, 2008; Naka et al, 2010;
Table 1. Main sarcoma subtypes discussed in this review and their
characteristics.
Sarcoma subtype Abbreviation Main features
Bone sarcomas
Chondrosarcomaa CHS • Localization: Cartilage, bone
surface, or centrally in bone
• Histopathology: Lobules
composed of malignant
chondrocytes entrapped in a
chondroid matrix with
calcified foci
• Identified mutations of
IDH1/2, EXT1/2
Ewing sarcomaa EwS • Localization: Long and flat
bones (~85%), extraskeletal
sites (~15%)
• Histopathology:
Undifferentiated small
round cells; mostly strong
membranous CD99
immunoreactivity and PAS-
positive cytoplasm
• Harbor somatic FET-ETS
translocations (~85%
EWSR1-FLI1; ~10% EWSR1-
ERG; ~5% rare subtypes)
Osteosarcomaa OS • Localization: Bone surface or
centrally in bone
• Histopathology: Neoplastic
cells with mesenchymal
morphology and frequent
polymorphism (epithelioid,
fusiform, round, spindled,
etc.) associated with an
extracellular osteoid matrix
• Various subtypes including
telangiectatic OS character-
ized by numerous hemor-
rhagic areas
• Complex highly aneuploidy
karyotypes with multiple
chromosomal aberrations
(numerical and structural)
• Frequent TP53 and RB
mutations and numerous
other mutations defining a
“BRCAness” signature
Soft Tissue Sarcomas (STSs)
Fibrosarcomaa • Localization: Deep soft tis-
sues of the extremities,
trunk, and head & neck
• Histopathology: Composed
of monomorphic fibroblastic
cancer cells in collagenous
matrix
GastroIntestinal
Stromal Tumors
GIST • Localization: Gastrointesti-
nal track (main site: stom-
ach and small intestine)
• Histopathology: broad mor-
phological spectrum with
mainly spindle cells and
epithelioid cells (~20% of
cases) or mixed histology
Table 1 (continued)
Sarcoma subtype Abbreviation Main features
characterized by differentia-
tion toward the interstitial
cells of Cajal. Usually
immunopositive for CD117
(KIT) and DOG1
• Harbor frequent activating
mutations in KIT and PDGFRA
Leiomyosarcoma LMS • Localization: Most com-
monly detected in the peri-
toneum and uterus (rarely
in bone)
• Histopathology: Mesenchy-
mal, spindle-shaped cells
with smooth muscle differ-
entiation (SMA, desmin and
h-Caldesmon positivity)
• Highly complex karyotypes
with genomic instability
Liposarcomaa LPS • Localization: Variable (most
commonly in the retroperi-
toneal space)
• Histopathology: Cancer cells
with variable adipocytic dif-
ferentiation and heteroge-
nous morphology embedded
in a vascularized stroma (in
case of myxoid LPS in myx-
oid stroma)
Rhabdomyosarcoma RMS • Localization: Variable
• Histopathology: Mesenchy-
mal phenotype with vari-
able myogenic
differentiation (usually posi-
tive for myogenin and MYOD)
Undifferentiated
pleomorphic
sarcomaa
UPS • Localization: Most fre-
quently in extremities
• Histopathology: Undifferen-
tiated cancer cells with a
high degree of cellular
atypia and pleomorphism
Synovial sarcoma SS • Localization: Mostly in deep
soft tissues of the extremi-
ties
• Histopathology: Spindle cells
with variable mesenchymal
and/or epithelial differentia-
tion (i.e., monophasic/bipha-
sic SS)
• Harbor specific SS18-SSX1/2/
4 fusion oncogenes
aThe most common bone sarcoma and STS subtypes (WHO Classification of
Tumours: Soft Tissue and Bone Tumours, 2020).
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Tumor dormancy and local recurrence
Agents targeting CSCs and 
drug resistance
• Mithramycin analogues (EC-8042)
• Metformin
• Salinomycin
• Histone deacetylase inhibitors
• TGF-β inhibitors
• NFκB inhibitors
Minimal residual disease and
tumor recurrence 
Metastatic
foci
Cell dissemination
Proliferative
cancer cell clones
Cancer
stem-like cell /
dormant cell
COMPLEX MICROENVIRONMENT 
Local immune tolerant
environment 
Extracellular matrix
components 
Extracellular
vesicles
• Osteocytes
• Chondrocytes
• …
Vasculature
Microbiome
• VEGF
• PDGF
• IL-6
• IL-8
• TGF-β
• RANKL
• TGF-α
• FLT3
• M-CSF
• IL-4
• IL-6
• IL-17
• IL-10
• IL-34
Polyclonal tumor
development
Additional
oncogenic and
epigenetic
events
First
oncogenic
event
Apoptotic
cell
Mesenchymal
stem cells
• TGF-β
• TGF-β
Cytotoxic agents
• Doxorubicin
• lfosfamide
• Methotrexate
• Docetaxel
• Gemcitabine
• Cisplatin
• Trabectedin
Targeted therapies
(targets) 
• Apatinib (VEGFR)
• Dasatinib (Src, KIT,
EPHA2, PDGFR) 
• lmatinib (PDGFR, KIT)
• Larotrectenib (NTRK)
• Nilotinib (BCR-ABL, DOR,
 KIT, PDGFR, M- CSFR) 
• Pazopanib (VEGFR,
 PDGFR, KIT) 
• Sorafenib (RET, VEGFR)
• Sunitinib (FLT3, PDGFR,
VEGFR, M-CSFR) 
• Bevacizumab (VEGF)
• Trastuzumab (HER2/neu)
• Ridaforolimus (mTOR)
• STAT3 inhibitors
• Tocilizumab (IL-6 receptor)
Agents targeting
microenvironment
and immune system 
• Bisphosphonates
• Anti-RANKL antibodies 
• Anti-PD-1/PD-L1
• Anti-GD2
• Anti-CD47
Cell types from
mesodermal tissues
• Adipocytes
• Myocytes
Figure 2.
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Riggi et al, 2010; Rodriguez et al, 2013; Basu-Roy et al, 2015, 2016;
Eid & Garcia, 2015; Tamaki et al, 2015; Abarrategi et al, 2016;
Almazán-Moga et al, 2017; Slemmons et al, 2017; Deel et al, 2018;
Genadry et al, 2018; Hatina et al, 2019; Rodrı́guez-Núñez et al,
2019; Schiavone et al, 2019; Trautmann et al, 2019). Alternatively,
both stemness and aggressiveness can be regulated by the interac-
tion with cells in the TME (Alfranca et al, 2015; Schiavone et al,
2019), or physical and chemical properties of the TME (i.e., hypoxia
and extracellular acidosis) (Zeng et al, 2011; Alfranca et al, 2015;
Avnet & Cortini, 2016; Avnet et al, 2017).
Several recent studies have focused on characterizing the
sarcoma-associated stroma and its effect on drug response
(Tarnowski et al, 2010; Ehnman et al, 2013; Baglio et al, 2017;
Cortini et al, 2017, 2019; Avnet et al, 2019). OS cells interact closely
with MSCs, CAFs, osteoblasts, osteocytes, osteoclasts, chondrocytes,
immune infiltrates, or components of the extracellular matrix to
drive stemness-promoting signaling (Avnet et al, 2008; Basu-Roy
et al, 2012; Zhang et al, 2013; Alfranca et al, 2015; Avnet & Cortini,
2016; Heymann et al, 2019). Moreover, MSCs/CAFs regulate tumor
growth and metastasis through PDGFRa/b and MIF-CXCR4/7 signal-
ing, enhancing sarcoma aggressiveness via the secretion of
inflammatory cytokines, exosomes (Miller et al, 2013; Cortini et al,
2016; Avnet et al, 2017; Baglio et al, 2017; preprint: Evdokimova
et al, 2019), or metabolites that can fuel the oxidative metabolism
of tumor cells (Bonuccelli et al, 2014). Metabolic fueling of sarcoma
cells by stromal cells may be particularly relevant to sustain the
energy demand of uncontrolled tumor growth and progression
(Zhang et al, 2010; Ren et al, 2017; Gaude et al, 2018; Zhu et al,
2019). Consequently, the composition of the local TME has direct
influence on the histological response to chemotherapy (Crenn et al,
2017). In addition, although axonogenesis has largely been
neglected in sarcoma preclinical modeling so far, increasing
evidence suggests that nerves in the TME may contribute to tumori-
genesis, progression, and cancer-associated pain in several sarcoma
subtypes, such as fibrosarcoma, OS, EwS, LPS, and extraskeletal
myxoid chondrosarcoma (CHS; Cain et al, 2001; Wacnik et al, 2005;
Endo et al, 2008; Ghilardi et al, 2010; Kanojia et al, 2015; Moriarity
et al, 2015; Shor et al, 2015; Brenca et al, 2019).
Moreover, the sarcoma TME may contain a specific microbiome
(Nejman et al, 2020): A recent study described that bacterial DNA
can be found in most CHSs. Bacteria were mostly intracellular and
were detectable in immune and tumor cells (Nejman et al, 2020).
Interestingly, metabolic functions related to intratumoral bacteria
appeared tumor type-specific; that is, degradation of hydroxyproli-
nes by bacteria was enriched in CHSs (Nejman et al, 2020).
Although more work is needed to decipher the precise role(s) of this
symbiotic microenvironment, it is tempting to speculate that it could
affect the stemness/differentiation and metabolic state of CHSs and
possibly other sarcomas.
To date, several clinical and preclinical studies have reported
treatments able to target the TME and/or CSCs in sarcomas (Abar-
rategi et al, 2016; Genadry et al, 2018; Schiavone et al, 2019)
(Fig 2). The advent of techniques for single-cell analysis, such as
single-cell DNA/RNA sequencing and spatial transcriptomics, will
accelerate studying and modeling of sarcoma tissue heterogeneity
and possibly lead to the identification of novel biomarkers and/or
therapeutic targets.
The immune infiltrate in sarcoma as a source of new
therapeutic targets
The TME of sarcoma cells is infiltrated by different immune cell
populations (Fig 3). For example, OS tumor tissues are infiltrated by
T lymphocytes (tumor-infiltrating lymphocytes, TILs) in a very high
percentage of patients, mainly expressing CD8+ (Théoleyre et al,
2005; Palmerini et al, 2017), and both TILs and tumor cells showed
a high expression of HLA-DR compared with other, non-malignant
bone tumors (Trieb et al, 1998). In preclinical models, CD8+ TILs
are cytotoxic against allogeneic tumor cells (Théoleyre et al, 2005),
and the number of CD8+ or CD8+/TIA1+ TILs correlates positively
with longer survival in patients (van Erp et al, 2017; Gomez-Brou-
chet et al, 2017; Palmerini et al, 2017). Similarly, in a small percent-
age of tumors, FOXP3+ (regulatory T cells, Tregs), and Arginase+
(myeloid-derived suppressor cells, MDSCs), immune-suppressive
infiltrating cells were detected (Fritzsching et al, 2015; Palmerini
et al, 2017). Notably, the CD8+/FOXP3+ ratio had a positive prog-
nostic value (Fritzsching et al, 2015). Furthermore, a high pretreat-
ment ratio of infiltrating neutrophils to lymphocytes, high levels of
C-reactive protein, Glasgow prognostic score, platelet–lymphocyte
ratio score, and lymphocyte-monocyte ratio or systemic absolute
leukocyte counts in post-therapeutic early recovery are independent
prognostic markers (Moore et al, 2010; Liu et al, 2016; Vasquez
et al, 2017).
Sarcomas are also frequently infiltrated by macrophages, which
represent the main immune infiltrate and a highly heterogeneous
population (Toulmonde et al, 2018; Mu et al, 2019; Stahl et al,
2019). Macrophage subpopulations are composed of a balance
between immune-stimulatory M1 and immune-suppressive M2
macrophages that can be dysregulated in sarcomas. Both subpopula-
tions are CD68+ and can be distinguished by the INOS and CD163
expression in M1 and M2 macrophages, respectively (Jayasingam
et al, 2020). However, their roles are complex, as revealed by the
functional discrepancy observed according to the given sarcoma
subtype. Indeed, CD163+ is required for their protumoral activities
(Shiraishi et al, 2018) and is a prognostic marker for specific
◀
Figure 2. Biological features of sarcomas and therapeutic approaches.
Sarcoma development results from a complex biological process. Their natural history combines the emergence of a first oncogenic hit followed by secondary oncogenic and
epigenetic events with a conjuncture of a permissive microenvironment composed by cell types from mesodermal tissues, immune infiltrate, vascular, and extracellular
matrix components. Sarcoma cells interact with their close environment through direct contact, enhanced cytokine/growth factors/miRNA signaling under a soluble form or
encapsulated in extracellular vesicles. Sarcoma cells are characterized by a phenotypic and genetic heterogeneity coming from the successive oncogenic/epigenetic events
occurring during tumor development and by cancer cells acquiring stemness properties that become progressively quiescent. Sarcomas are prone to induce distant
metastatic foci spread by circulating tumor cells and invading after extravasation appropriate metastatic niches. Cancer cells installed in distant organs can spread again
and enrich other metastatic sites increasing the tumor heterogeneity and potentially drug resistances. Persisting cells after resection of the primary tumor or dormant
cancer cells located in distant organs characterize the minimal residual disease and are responsible of tumor recurrences. A selection of approved and experimental
treatments aimed to prevent tumor growth and/or dissemination is shown.
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sarcoma subtypes such as embryonal rhabdomyosarcoma (ERMS;
Kather et al, 2019), whereas in OSs, CD163+ M2 macrophages are
proangiogenic, facilitating cancer cell extravasation and promoting
the metastatic process (Dumars et al, 2016; Han et al, 2016; Gomez-
Brouchet et al, 2017). Conflicting results showed a positive associa-
tion of tumor-associated dendritic cells (CD1a+) and macrophages
with either a worse disease-free survival (Koirala et al, 2016) or
inhibition of metastases (Buddingh et al, 2011). However, their
phenotype has not been fully characterized.
Sarcomas driven by reciprocal fusion oncoproteins, such as EwS,
generally exhibit a low immune infiltrate, constituting so-called
“cold” tumors. Few available studies have demonstrated that TILs
and dendritic cells are quite rare (immune desert) and that
programmed death-ligand 1 (PD-L1) expression is usually low
(Spurny et al, 2018). The presence of infiltrating macrophages has
been associated with poorer overall survival (Vakkila et al, 2006),
and elevated levels of circulating proinflammatory factors (e.g.,
interleukin 6, IL-6) correlate with tumor-associated fever at
advanced stages (Lissat et al, 2015), implying the recruitment of
immunosuppressing myeloid dendritic cells, macrophages, and
other inflammatory cells at the tumor site (preprint: Evdokimova
et al, 2019).
For STSs, only a very few recent reports have aimed to determine
the “hot” or “cold” tumor immunophenotypes and their potential as
biomarkers for response to therapy (Galon & Bruni, 2019). Kim et al
reported the presence of PD-1+ and PD-L1+ TILs at rates of 65%
and 58%, respectively, in various STS subtypes (Kim et al, 2013a).
Similarly, the infiltrations of PD-L1-expressing macrophages and
lymphocytes were observed in 58% and 30%, respectively, of 50
analyzed STS samples (D’Angelo et al, 2015), and the PD-L1
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Figure 3. Sarcomas are characterized by an immune oasis.
Sarcomas are infiltrated by numerous immune cells, which are in some sarcoma subtypes deleterious by establishing an immune tolerant microenvironment that can be at
the origin of innovative therapeutic approaches. In physiological condition, the adaptive immune system is activated by exogenous antigens leading to initiation of an
effective immune response against the host at the origin of these antigens. Unfortunately, inmost cases immune activation by tumor-associated antigen is counterbalanced
by inhibitory signals transmitted after the binding of immune checkpointmolecules (e.g., PD-1) expressed by immune effectors to their ligands expressed by cancer cells such
as PD-L1. Macrophages also contribute to the immune surveillance in sarcomas with two main distinct subsets: M1 macrophages with pro-tumor activities and M2
macrophages with anti-tumor and immunosuppressive functions. This immune landscape has led to the development of immunotherapies including immune checkpoint
inhibitors, activated NK cells, or genetically modified T lymphocytes (CAR T cells) in order to reactivate the tumor immune surveillance.
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expression was associated with a higher density of CD3+ PD-1+
TILs, a higher tumor grading, and a lower overall survival (Orth
et al, 2020). PD-L1 was also expressed by tumor cells in 12% of
cases, with the highest prevalence in gastroIntestinal stromal tumors
(GISTs). Finally, the detection of low CD3+ or CD4+ TILs was
significantly correlated with better overall survival by a univariate
analysis (D’Angelo et al, 2015). However, recent reports have
provided a more panoramic view of PD-1 and PD-L1 expression in
larger series of STS and revealed that most STS subtypes show
expression of both factors (Dancsok et al, 2019; Orth et al, 2020).
However, the bioclinical relevance of PD-1 and PD-L1 (e.g., prog-
nostic value) remains controversial in sarcomas, mainly due to their
high heterogeneity (Fujii et al, 2014; Nduom et al, 2016; Nowicki
et al, 2017).
Collectively, the immune infiltrates observed in sarcomas offer a
rich opportunity for implementation of immunotherapeutic
approaches in sarcomas. Yet, a complete and more standardized
immune score may help to better understand the different
immunophenotypes related to each sarcoma subtype and to improve
immunotherapeutic approaches.
Models for studying the biology of sarcomas
Human cancer cell lines have become the cornerstone of cancer
research. However, the accumulation of (epi-)genetic mutations
over time and across laboratories can have crucial implications
when investigating new treatments as shown in carcinoma cell lines
(Liu et al, 2019), since they affect drug response (Ben-David et al,
2018). Whether this holds true for translocation-driven sarcomas,
such as alveolar rhabdomyosarcoma (ARMS), EwS, myxoid LPS,
and SS, which display rather “silent” genomes, remains to be deter-
mined. Yet, the use of low-passaged primary cell lines can prevent
accumulation of mutations: A recent study of CHS patient samples
and their derived cell lines characterized the genetic drift process of
primary cell lines after 20–34 in vitro cell culture passages (Rey
et al, 2019). Although the adaptation of tumor cells to in vitro cell
culture is accompanied by additional genetic mutations, these rather
low-passaged CHS cell lines retained the most relevant mutations of
the patient’s founder clone (Rey et al, 2019).
For preclinical modeling of sarcoma, 3D culture has recently
emerged as a tool for better prediction of drug efficacy and develop-
ment of precision medicine approaches (Vaira et al, 2010; Santoro
et al, 2015; Bregenzer et al, 2019). These 3D models include
microfluidic devices, bioprinted cell-enriched structures with tailor-
able biomechanical properties, and well-defined tumoroids (Murphy
& Atala, 2014), which contain different cell types, defined gradients
of bioactive factors, and “physiological” biomaterials to precisely
recapitulate the natural TME (Ma et al, 2018). This will help to
elucidate the mechanical cross-talk between sarcoma cells and
“normal” cells (including vasculature and immune cells) (Huang
et al, 2014; Datta et al, 2017), as well as components of the extracel-
lular matrix (Doraiswamy et al, 2007; Pavlou et al, 2019). However,
although a recent study has successfully employed a mineralized 3D
bone model to evaluate the effect of the small-molecule elesclomol
on EwS cells (Marchetto et al, 2020), 3D models for the study of
sarcoma are still in their infancy (Barron et al, 2004, 2005).
In vivo, the chick chorioallantoic membrane (CAM) assay is a
valuable option due to its low costs and relatively easy implementa-
tion. CAM assays have been employed to study sarcoma
angiogenesis, fibroblast infiltration, tumorigenesis, tumor invasion,
and metastasis in CHS, EwS, fibrosarcoma, LPS, and OS (Sys et al,
2013; Patil et al, 2014; Manjunathan & Ragunathan, 2015; Cimpean
et al, 2018; Kunz et al, 2019; Perut et al, 2019; Steinestel et al,
2020). Numerous additional in vivo models of inducible or sponta-
neous sarcomas have been described in non-mammalian vertebrates
(e.g., zebrafish; Leacock et al, 2012; Mohseny et al, 2012; Brown
et al, 2017b; Hayes & Langenau, 2017; Ignatius et al, 2018; Fleming
et al, 2019) and in mammalians (e.g., mouse, rat, and dog; Cannon,
2015; Jacques et al, 2018; Castillo-Tandazo et al, 2019; Pomella &
Rota, 2020). Genetically modified zebrafish and xenotransplantation
of human sarcoma cells in fish were simultaneously proposed. Their
main advantages are (i) their small size, allowing the maintenance
of many animals at low costs; (ii) their high rate of proliferation
(> 200 embryos per pairing); (iii) ex utero development of embryos,
facilitating cell transplantations; (iv) their transparency, which facil-
itates non-invasive and repeated imaging; (v) the possibility of
imaging at the single-cell level; (vi) studies of human cells and host
factors facilitated by the use of transgenic lines; (vii) no immune
rejection in early cell transplantation; and (viii) facilitation of high-
throughput drug screening due the animals’ permeability to small
molecules through diffusion. Yet, the lack of specific organs (e.g.,
lungs) and the difference with human TME are two major limita-
tions of zebrafish models (Mohseny et al, 2012; Brown et al, 2017b;
Hayes & Langenau, 2017).
Genetically engineered mouse models (GEMMs) are considered
reliable models for studying cancer development. Indeed, by induc-
ing the formation of spontaneous tumors mimicking the natural
history of human pathologies, GEMMs are privileged models to
functionally identify and characterize molecular drivers or genetic
initiator events of the disease (Kersten et al, 2017). While EwS, for
which no bona fide GEMMs have been developed to date, is an
exception among sarcomas, numerous GEMMs of bone sarcomas
(for reviews, see ref. Jacques et al, 2018, 2019) and STSs (for
review, see ref. Dodd et al, 2015) have been described. The first
GEMM overexpressed the AP-1 transcription factor c-Fos in murine
osteoblasts, which led to the development of OS without inducing
metastatic foci (Grigoriadis et al, 1993). More recent models include
deletion of Tp53, Rb, Prx-1, or Prkar1a; overexpression of Sonic
Hedgehog signaling components; or targeting Apc and Twist, and
lead to the formation of metastatic OS (Jacques et al, 2018). Simi-
larly, conditional loss of Tp53 or Ink4a/Arf in an Ext1-driven GEMM
results in the formation of CHS (de Andrea et al, 2015).
GEMMs of STSs were also developed (Dodd et al, 2015). For
example, the conditional Pax3-Fkhr knock-in allele is associated
with the development of ARMS with a frequency that can be
increased by the loss of function of Ink4a/ARF and Tp53 (Keller
et al, 2004). In addition, ERMS can be induced from the adipocyte
lineage by adipocyte-restricted activation of Hedgehog signaling
through constitutive expression of an active Smoothened allele (Hat-
ley et al, 2012). The latter model has also helped to demonstrate
that Hedgehog signaling drives aberrant expression of myogenic
specification factors, which may induce ERMS from non-myogenic
endothelial progenitors (Drummond et al, 2018). More recently,
GEMMs for sarcomas have been obtained by CRISPR-Cas9 technol-
ogy (Huang et al, 2017).
Xenografts are alternatives to GEMMs and can be obtained by
injection of tumor cells into immunodeficient mice. Xenografts are
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relatively easy to generate and highly reproducible (Picarda et al,
2010; Gambera et al, 2018; Jacques et al, 2018), but cannot fully
recapitulate the TME of many sarcoma subtypes, and only rarely
give rise to spontaneous metastases (Jacques et al, 2018). In this
context, orthotopic xenografts obtained through injection of a
suspension of tumor cells into the para- or intraosseous site for OS
and EwS modeling (Hauer et al, 2013; Lamora et al, 2014; Stewart
et al, 2014; Ségaliny et al, 2015; Baglio et al, 2017), or through
intramuscular injection for the modeling of “soft tissue EwS”
(Jaboin et al, 2002; Merchant et al, 2004), more closely recapitu-
lated the TME of the respective tumor histotype. Similarly, early
passage patient-derived xenografts (PDXs) constitute a powerful tool
for preserving the TME, histology, and genetic profiles of sarcomas
(Hoffman, 2015; Stewart et al, 2017). PDXs are obtained through
subcutaneous or orthotopic implantation of small fragments of
tumors isolated from patients in immunodeficient mice. However,
so far, only few studies have been published on PDXs in sarcoma
due to the low success rate of the engraftment, the complex implan-
tation procedure (Stewart et al, 2017; Nanni et al, 2019; Rainusso
et al, 2019), and the costs required for the stabilization of the
model, which may require up to a year (Nanni et al, 2019).
Current standard therapies for sarcomas
The therapeutic care of bone sarcoma and STS patients requires
specialized sarcoma units. In fact, treatment in such specialized
centers has been shown to result in improved surgical and oncologic
outcomes (Blay et al, 2017). In addition, due to the potentially
devastating consequences that can arise from poorly performed
biopsies, biopsies of lesions suspected of being a sarcoma should be
carried out in (or directed by) a specialized center (Mankin et al,
1982; Potter et al, 2008; Pretell-Mazzini et al, 2015; Traub et al,
2018). The cornerstone of bone sarcoma and STS management is
surgical resection of the primary tumor, which is typically accompa-
nied by neoadjuvant and/or adjuvant chemotherapy and/or irradia-
tion. Radiation therapy contributes to local control of tumor growth
with positive margins or high-grade STS (Kim et al, 2008).
Chemotherapy regimens of bone sarcomas (e.g., OS, EwS) combine
doxorubicin, cisplatin, methotrexate, and ifosfamide administered
before and/after surgery for 6–12 months (Brown et al, 2018). Simi-
larly, systemic treatments of STSs are mainly based on anthracycli-
nes (e.g., doxorubicin) alone or in combination with an alkylating
agent (e.g., ifosfamide) (Judson et al, 2014; Gómez & Tsagozis,
2020; Smrke et al, 2020). Interestingly, the use of adjuvant
chemotherapy or radiotherapy may be defined by biological risk
factors in high-risk STSs (Sundby Hall et al, 2018). Although
systemic therapy is the treatment of choice in metastatic disease
(Meyers, 2015), resection of the primary tumor may still be
performed with palliative intent, or rarely, in combination with
resection of oligometastatic disease (Blakely et al, 2015). Wide
margin surgery then remains the crucial technical approach in
sarcoma treatment (Patrikidou et al, 2011).
For bone sarcomas, studies have demonstrated that oncologic
outcomes of OS and EwS are similar between limb salvage and
amputation when wide margins are achieved (Simon et al, 1986;
Rougraff et al, 1994; Alamanda et al, 2012; Jauregui et al, 2018).
Thus, the current standard of care is limb salvage surgery if
preservation of neurovascular structures allows reconstruction of a
functional extremity (Yang et al, 2017). Special considerations are
made for limb reconstruction in the growing child, such as the use
of growing prostheses, vascularized autografts, or van Nes rotation-
plasty. The choice of (neo)adjuvant treatment modalities is largely
driven by the histological subtype: For instance, OS and EwS are
usually chemosensitive and treated with neoadjuvant and adjuvant
chemotherapy to decrease the risk of systemic disease progression,
while STSs are frequently treated with neoadjuvant radiation ther-
apy to decrease the risk of local recurrence (Gaspar et al, 2015;
Brown et al, 2018; Le Cesne, 2018; Ray-Coquard et al, 2018; Fig 2).
In contrast, high-grade CHS is largely resistant to existing chemo-
and radiotherapies; thus, achieving a wide margin resection is
currently the best option for prevention of disease progression (Reed
et al, 2017; Brown et al, 2018; Whelan & Davis, 2018).
GIST is one of the STS subtypes for which the therapeutic devel-
opment has been the most spectacular (Farag et al, 2020). For
instance, up to 85% of patients with advanced GIST benefit from
imatinib treatment (Blay, 2011). In fact, 90% of GISTs harbor driver
mutations in the KIT proto-oncogene receptor tyrosine kinase (KIT)
and platelet-derived growth factor receptor alpha (PDGFRA), which
can be targeted by tyrosine kinase inhibitors (TKIs). Their therapeu-
tic efficacy is directly linked to the type of mutation, and conse-
quently, the acquisition of secondary mutations can result in drug
resistance (see section “Resistance to targeted therapies”), which
remains the most significant challenge in the treatment of locally
advanced and metastatic GIST (Li & Raut, 2019). However, even
fourth-line therapy with TKIs may still be effective in advanced GIST
(Blay et al, 2020).
Yet, the mostly moderate efficacy of any second-line treatment
for the majority of relapsed bone sarcomas and STSs highlights the
need for intensified research to identify novel targets and improved
preclinical models to predict drug response in molecularly defined
cohorts of patients suffering from refractory and/or recurrent
disease.
Mechanisms of drug resistance
Chemoresistance has been largely associated with the expression of
specific detoxifying molecules, such as efflux pumps (ATP-binding
cassette (ABC) family proteins or ALDH enzymes), as it has also
been recently demonstrated for CSCs (Lohberger et al, 2012). In
particular, P-glycoprotein is a 170 kDa transmembrane energy-
dependent efflux pump encoded by the MDR1 gene. Its expression
leads to a multidrug resistance phenotype rather than an increased
biological aggressiveness (Scotlandi et al, 1996; Baldini, 1997),
which is associated with decreased event-free survival in OS
patients (Baldini et al, 1995) and in a small percentage of STS
patients (Serra et al, 1996), and has also recently been found in
bone sarcoma PDXs (Nanni et al, 2019).
Besides P-glycoprotein, additional drug resistance mechanisms
are caused by tumor heterogeneity arising from high DNA repair
capacity, deregulation of apoptotic factors, adoption of a quiescent
state (Honoki et al, 2010; Abarrategi et al, 2016; Martinez-Cruzado
et al, 2016; Roundhill et al, 2019; Vallette et al, 2019), drug delivery
failure, the epithelial–mesenchymal transition (EMT) (Sannino et al,
2017), increased autophagy (Xiao et al, 2018), enrichment of CSCs
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(Eyler & Rich, 2008), protective signaling traits after chemothera-
peutic treatment (Martins-Neves et al, 2016; Yu et al, 2016), and
immune evasion (Vasan et al, 2019).
In addition, resistance to conventional TKIs (e.g., imatinib) is
associated with secondary mutations of KIT or PDGFRA in GIST (see
section “Resistance to targeted therapies”). To overcome such
acquired resistance, “switch pocket inhibitors” have been developed
(Blay et al, 2020). A switch pocket inhibitor has the same target as
the conventional inhibitors but acts like a light switch that deacti-
vates cell signaling associated with the targeted receptor via block-
ing conformational activation of the kinase. For example, ripretinib
targets KIT, PDGFRa/b, kinase insert domain receptor (KDR), and
colony-stimulating factor 1 receptor (CSF1R alias C-FMS) and has
been developed to overcome the TKI resistance occurring in GIST
patients. The Asp842Val (D842V) mutation of PDGFRA was identi-
fied as the primary driver mutation in 5–6% of GISTs, which are
refractory to all currently approved TKIs (Corless et al, 2005). The
D842V mutation is located in the exon 18 encoding the PDGFRA
activation loop and modifies the protein conformation to a “consti-
tutive” active form.
Avapritinib is a new TKI designed on the base of its selectively
property to target the active conformation of KIT and PDGFRA. A
phase I clinical trial (ClinicalTrials.gov No. NCT02508532) has
recently assessed its safety, tolerability, and anti-tumor activity
(Heinrich et al, 2020). Interestingly, 9% of complete response and
79% a partial response was observed. Ripretinib—an inhibitor of all
known KIT and PDGFRA mutations—forces the switching of the
mutated receptors to assume the “off” position. A recent double-
blind, randomized, placebo-controlled, phase 3 clinical trial (Clini-
calTrials.gov No. NCT03353753) showed that ripretinib significantly
improved the progression-free survival with an acceptable safety
profile in patients suffering from advanced GIST resistant to
approved treatment (Blay et al, 2020).
Similarly, the classification of BRAF mutations, the knowledge
about dysregulated signaling pathways and dysregulated circuitries
related to these mutations, and the function of BRAF in sarcoma led
to the development of new therapeutic options to overcome resis-
tance to conventional chemotherapy. For instance, the BRAF V600E
mutation was recently identified as a potential therapeutic target in
a small subset of SS (Watanabe et al, 2020). It is interesting to note
that resistance to BRAF mutation inhibitors may be overcome by
combining BRAF inhibitors with EGFR, PI3K, mTOR, MEK, RTK,
HGF, and MET inhibitors, leading to the targeting of the MAPK and
PI3K-AKT-mTOR signaling pathways (Liu et al, 2020). CX-6258 is a
pan-Pim kinase inhibitor selected for its potent activity against
sensitive and resistant cancer cells to RAF/MEK inhibitor (Haddach
et al, 2011).
Using a KINOMEscan assay platform, haspin kinase was identi-
fied as a target of CX-6258. The inhibition of haspin reduced cancer
cell proliferation and regulated the immune system by increasing
the frequency of interferon c (IFNc)-producing CD8+ T cells and
reducing the number of Tregs in vivo (Melms et al, 2019). Interest-
ingly, the haspin kinase inhibitor can overcome RAF/MEK inhibitor-
resistant cancer cells and shows anti-tumor effects in EwS (Melms
et al, 2019). Acquired resistance to cisplatin observed in OS patients
is associated with a poor prognosis (Higuchi et al, 2019). Peroxi-
some proliferator-activated receptor gamma (PPARc) was reported
to enhance the efficacy and overcome resistance to cisplatin in
various oncological entities and exhibits similar properties in OS
(Higuchi et al, 2019).
The cell differentiation state also affects drug sensitivity (Dawson
et al, 2020). A subpopulation of RMS cells that expressed MYOD1
and NOG exhibited primary resistance to vincristine and doxoru-
bicin, which can be partly overcome by the combination of 12-O-
tetradecanoylphorbol-13-acetate (TPA) and an enhancer of zeste
homolog 2 (EZH2) inhibitor (GSK126) (Dawson et al, 2020). EZH2
is an epigenetic drug acting as a histone methyltransferase inhibitor
that has been recently approved for metastatic or locally advanced
epithelioid sarcoma (Rugo et al, 2020). The elimination and recy-
cling of damaged proteins and organelles are driven by autophagy,
which provides energy to the cells. Autophagy can be activated by
chemotherapy and can promote increased chemosensitivity, as well
as drug resistance in OS (Camuzard et al, 2019; Liao et al, 2019).
Thus, drugs regulating autophagy may be an option to overcome
drug resistance in the future.
Cell dormancy and recurrence
The risk of recurrence in oncology is associated with the persistence
of cancer cells, which are not clinically/biologically detectable after
resection of the primary tumor (Arlt et al, 2013). The latency with-
out any detectable disease varies according to the clinical condition
(e.g., histological grade and subtype) and depends on cancer cells
characterized by slow cycling, low metabolism and fitness, and
consequently, long-term survival mechanisms (Vallette et al, 2019).
Awakened cancer cells re-acquire an active state, with capacities of
proliferation and spreading to distant sites, and they define the mini-
mal residual disease (Riethmüller & Klein, 2001). Dormant cells
have been identified in several sarcoma subtypes, including
fibrosarcoma (Dobson & Dickey, 1956; Varani et al, 1981; Cao et al,
1998), LPS (Almog et al, 2006; Rogers et al, 2014), RMS (Kimura
et al, 2002), Kaposi sarcoma (Indraccolo et al, 2006), and OS (Nau-
mov et al, 2006; Shimizu et al, 2014; Avril et al, 2016a,b; Guo et al,
2017). These rare dormant cells exhibit stemness properties (Vis-
vader, 2011), and they have been related to drug resistance (De
Angelis et al, 2019; Smith & Macleod, 2019; Vallette et al, 2019).
The emergence of dormant cells is a conserved biological process
linked to cell survival and controlled by multiple parameters,
including genetic and epigenetic alterations, clonal cell evolution,
cell–matrix interactions within the TME (e.g., immune tolerance),
and diversity/heterogeneity. No specific molecular signature of
dormant sarcoma cells has yet been identified. The most recent
molecular approaches (e.g., single-cell RNA sequencing, RNA/DNA
methylation profiling) should lead to the identification of their speci-
fic molecular profile and of the molecular drivers of this state. For
instance, myeloma dormant cells are switched “on” by engagement
with osteoblastic cells and switched “off” by active osteoclasts
(Lawson et al, 2015), which illustrates the clinical interest of target-
ing cell dormancy also in the context of bone sarcomas and STSs
(Endo & Inoue, 2019; Recasens & Munoz, 2019; Tellez-Gabriel et al,
2019).
Resistance to targeted therapies
TKIs are the largest class of targeted therapies approved by the Food
and Drug Administration (FDA). In particular, GIST commonly
shows activating mutations in the receptor tyrosine kinases KIT and
PDGFRA. While physiological KIT or PDGFRa signaling are involved
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in cell differentiation and survival, activating mutations in both
genes results in constitutive ligand-independent receptor activation,
leading to GIST tumorigenesis. TKIs are the standard of care in the
primary treatment of GIST, and imatinib is the most commonly used
compound (Casali et al, 2018). The resistance toward TKIs in GIST
is mainly related to secondary mutations of KIT (Li & Raut, 2019;
Napolitano & Vincenzi, 2019), but can also be triggered by PDGFRA
mutations (Lim et al, 2008; Kalfusova et al, 2019).
In non-GIST STSs, the currently approved targeted therapies are
limited to the multi-target TKI pazopanib, which targets VEGFR-1,
VEGFR-2, and VEGFR-3, PDGFRa and PDGFR-b; and KIT (Lee et al,
2019). It has been demonstrated that anti-angiogenic TKIs, including
pazopanib, do not succeed in targeting sarcoma stem cells (Canter
et al, 2014), whereas treatment with pazopanib in a human SS
model promotes the development of resistance (Lanzi et al, 2019).
Despite a strong inhibition of the main target of pazopanib,
PDGFRa/b, the activation of the AKT and ERK signaling pathways
was only partially impaired, possibly due to the over activation of
other tyrosine kinase receptors, including the insulin-like growth
factor receptor type 1 (IGF1R) and insulin receptor (IR). Similarly,
in another SS cell line, the presence of an NRAS mutation sustained
ERK activation and caused resistance to pazopanib treatment (Lanzi
et al, 2019). Thus, a combination treatment with either an IGF1R/IR
inhibitor or a MEK inhibitor has been suggested to restore the inhi-
bition of the PDGFRa/b pathways and effectively promote apoptosis
(Lanzi et al, 2019). Phosphoproteomic profiling of pazopanib-resis-
tant cells identified the inhibition of HSP90 as a therapeutic route to
overcome resistance (Vyse et al, 2018).
These findings highlight the importance of patient-specific tumor
profiling to identify the underlying activated signaling pathways,
thereby avoiding the “one-size-fits-all” paradigm and moving
toward personalized, multi-line, and patient-specific treatment regi-
mens (Wilding et al, 2019). Biomarker-guided basket trials, such as
the CREATE trial, which evaluates multiple disease types with a
common oncogenic driver matched to a specific targeted therapy,
may be considered in this respect (Péron et al, 2019). Moreover,
characterization of interpatient pharmacokinetic variability will be a
valuable tool to predict and overcome the development of resistance
(Cardoso et al, 2020).
Other types of resistances
Several other indirect mechanisms of drug resistance in sarcoma
have been identified, such as the formation of abnormal TME,
hypoxia, and acidosis. Elevated levels of hypoxia and hypoxia-indu-
cible factor 1a (HIF1a) in human sarcomas correlate with tumor
progression and radiation resistance (Kim et al, 2013b). In particu-
lar, in STS, HIF1a expression was found in 25.5% of tumors and
was associated with both shorter overall survival and progression-
free survival (Kim et al, 2015). Moreover, translational activation of
HIF1a by YB-1 was found to promote metastasis in preclinical
models of EwS, OS, and RMS (El-Naggar et al, 2015). Similarly, in
OS, hypoxia was responsible for the induction of the Wnt/b-catenin
signaling pathway and resulted in 6–13 times more cell resistance to
doxorubicin-mediated toxicity than under normoxic conditions
(Roncuzzi et al, 2014; Scholten et al, 2014). In EwS, hypoxia has
been found to protect tumor cells against anticancer drugs, while
suppression of HIF1a enhanced drug-induced apoptosis (Kilic et al,
2007). Accordingly, metabolic characterization, including hypoxic
phenotypes, may help to identify specific treatment modalities in
OS, other bone sarcomas, and STSs (Eary et al, 2011; Campanile
et al, 2013). Along these lines, a recent pilot study characterized dif-
ferent metabolic parameters in a small group of STS patients using
specific positron emission tomography (PET) agents to assess the
individual risk associated with biological characteristics of the
tumors (Wolsztynski et al, 2018).
Tumor acidosis is a metabolic adaptation observed in cancers
and characterized by the fermentation of glucose to lactic acid. This
process occurs in the presence of oxygen and is called aerobic
glycolysis or Warburg effect. This adaptative mechanism modulates
the drug sensitivity and leads to drug resistances by intrinsic (e.g.,
modulation of the mutational profile driven by a cell adaptation to
stress) or extrinsic (e.g., structural/functional modulation of drugs
induced by the local pH modifications) mechanisms (Kolosenko
et al, 2017). Indeed, the pH of the local microenvironment regulates
the passive diffusion of small molecules such as cancer drugs across
biological barriers by modulating charged components of cell
membranes, process named ion trapping or pH-partitioning (Scott
et al, 2017). Many cancer drugs are ionizable molecules containing
weak bases or acids in their structure and are subjected to pH-parti-
tioning resistance (Zhitomirsky & Assaraf, 2016). That is the case
for doxorubicin (weak base compound) in OS, which is trapped in
the acidic extracellular microenvironment and consequently cannot
target cancer cells (Avnet et al, 2016). On the contrary, the cytotoxic
effects of cisplatin (weakly acidic drug) are increased in OS by the
local tumor acidosis, which favors its neutral form and then facili-
tates its passive diffusion across the cell membranes (Avnet et al,
2016). In the cytoplasm, cisplatin is ionized by the low alkaline pH
and trapped in the cell. A similar phenomenon was described in
RMS, and the diffusion of weak base drugs across cell membranes
and their sequestration in the lysosomal compartment are facilitated
by ion trapping (Salerno et al, 2014; Zhitomirsky & Assaraf, 2016).
Molecular signatures of sarcomas: Effects on diagnosis
and prognosis
In past decades, an unbiased and systematic search for gene fusions
combined with unsupervised gene expression and (epi)genetic anal-
yses of different sarcoma subtypes led to better classification
systems (WHO Classification of Tumours: Soft Tissue and Bone
Tumours, 2020). In addition, these molecular signatures provide
information about the biology of these tumors, reflecting both the
characteristics of the sarcoma’s cell of origin and the activated path-
ways driving the malignant phenotype (Taylor et al, 2011).
Genomic and transcriptomic alterations
The Cancer Genome Atlas (TCGA) Research Network reported a
recent analysis of 206 adult STSs representing six major subtypes
(Cancer Genome Atlas Research Network, 2017). Here, the authors
showed that common sarcomas (except for SS) are characterized by
a high number of copy-number variations (CNVs) and recurrent
point mutations in relatively few genes, such as TP53, ATRX, and
RB1. Importantly, specific genomic and transcriptomic alterations
also define molecular subtypes, which are associated with patient
outcome (Cancer Genome Atlas Research Network, 2017). Other
studies have identified whole-genome duplication as a cause of the
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structural complexity of UPS (Steele et al, 2019), and CDKN2A alter-
ations as a predictor of worse overall survival across sarcoma
subtypes (Bui et al, 2019). Integrated analysis of genomic and tran-
scriptomic data confirmed the mutational profiles of STSs and iden-
tified PDGFRa as a putative target in complex karyotype STSs (Kim
et al, 2018). Indeed, a PDGFRa-blocking antibody (olaratumab) in
combination with doxorubicin showed promising results for non-
GIST STS treatment (Klug & Heinrich, 2017). Given the widespread
presence of CDK4-amplification/high expression and CDKN2A loss
across sarcomas subtypes, CDK4 inhibitors such as palbociclib are
also a promising strategy in RB-positive tumors (Dickson et al,
2013). It is noteworthy that ATRX has been shown to be required
for response to CDK4 inhibitors in LPS, providing a potential
biomarker for upcoming clinical trials (Kovatcheva et al, 2015;
Cancer Genome Atlas Research Network, 2017). Integration of
genomic and transcriptome analysis has also uncovered a “BRCA-
ness” mutational signature in LMS, which confers sensitivity to
DNA double-strand break-inducing drugs (Helleday, 2011; Chuda-
sama et al, 2018) and sensitivity toward the combination of the poly
(ADP-ribose) polymerase (PARP) inhibitor olaparib and cisplatin
(Chudasama et al, 2018). Olaparib combined with trabectedin (an
alkylating drug) showed manageable toxicities at active dose levels
and encouraging anti-tumor activity in STS (Grignani et al, 2018). A
phase 2 study on this topic is ongoing (ClinicalTrials.gov No.
NCT04076579).
Exome sequencing has revealed a combination of single-base
substitutions, loss of heterozygosity events, and/or large-scale
genome instability involving 14 driver genes (ATM, ATRX, BAP1,
BRCA2, FANCA, MDC1, MUTYH, NUMA1, PTEN, RB1, RECQL4,
RET, TP53, and WRN) and many additional genes that define a
“BRCAness” signature in > 80% of OS (Kovac et al, 2015). In fact,
OS is characterized by a very complex altered genomic landscape
explained by chromothripsis-generating driver mutations and multi-
ple genomic rearrangements (Behjati et al, 2017). However, in some
cases, OS tumorigenesis is associated with germline alterations in
TP53, RB1, and RECQL1/2/3 predisposing patients to the accumula-
tion of high numbers of somatic mutations (Smida et al, 2017;
Baumhoer et al, 2019; Sayles et al, 2019). In addition, two recent
publications hypothesized that specific somatic CNV profiles of OS
can be used for outcome prediction and for identification of altered
genes and associated pathways as potential therapeutic targets
(Smida et al, 2017; Sayles et al, 2019). Similar preliminary findings
have been reported for EwS and RMS (Cheng et al, 2019). Olaparib
combined with ceritinib (ALK inhibitor) in OS showed limited toxic-
ity and should be further evaluated (Beck et al, 2020). A clinical
trial assessing olaparib combined with ceralasertib (ATR inhibitor)
is currently in progress in the context of OS (ClinicalTrials.gov No.
NCT04417062).
In contrast to OS and most sarcomas of adulthood, translocation-
driven pediatric sarcomas, such as EwS, SS, or fusion-positive
ARMS, exhibit much lower rates of single-nucleotide variants and
CNVs, and, instead, appear to be driven by marked epigenetic and
transcriptomic perturbations induced by the fusion oncoproteins
(Shern et al, 2014; Tirode et al, 2014; Cancer Genome Atlas
Research Network, 2017). In fact, through the integration of tran-
scriptomic and genetic data, a recent study found that EWSR1-FLI1
hijacks the developmental transcription factor SOX6 and thus
promotes proliferation of EwS cells, which provides opportunities
for targeted therapeutic intervention for the oxidative stress inducer
elesclomol (Marchetto et al, 2020). New molecular studies have also
shed light on the role of the interplay between germline variants
and somatic mutations in interindividual tumor heterogeneity in
EwS (Musa & Grünewald, 2020). Musa et al recently showed that
EWSR1-FLI1 binds to a polymorphic enhancer-like GGAA-microsa-
tellite, through which it regulates the expression of the oncogenic
transcription factor MYBL2 (Musa et al, 2019). Importantly, vari-
ability at this MYBL2-associated GGAA-microsatellite is inherited
via the germline and linked to intertumoral variation in MYBL2
expression (Musa et al, 2019). As MYBL2 is phosphorylated and
activated by CDK2 (Musa et al, 2017), high MYBL2 expression
sensitizes EwS cells to CDK2 inhibition, indicating the potential for
using MYBL2 as a biomarker in anti-CDK2 therapy (Musa et al,
2019).
While oncogenic gene fusions involving transcription factors
remain largely undruggable (Knott et al, 2019), clinical trials
using larotrectinib, a kinase inhibitor targeting gene fusions
involving NTRK1/2/3, have shown promising results and could
offer a strategy for the treatment of NTRK-fusion-positive sarco-
mas (Doebele et al, 2015; Fig 3). In addition, DNA minor groove-
binding agents in DNA, such as trabectedin or mithramycin, have
been described as potent inhibitors of EWSR1-FLI1-mediated tran-
scription with anti-tumor potential (Bailey et al, 2019; Harlow
et al, 2019). A recent clinical trial showed that mithramycin was
too toxic at the dose required to inhibit EWSR1-FLI1 (Grohar
et al, 2017). However, the development of less toxic second-
generation mithramycin analogs, such as EC-8042, opens the
possibility of using this compound clinically (Osgood et al, 2016;
Tornin et al, 2016; Fig 3).
Epigenetic alterations
Mutations in chromatin remodeler components have recently been
recognized as oncogenic drivers in adult and pediatric sarcomas
(Nacev et al, 2019). Recurrent somatic missense mutations in
histone H3 at lysine 36 impair the mesenchymal differentiation
program and promote the initiation of UPS (Fang et al, 2016; Lu
et al, 2016). These mutations result in hypomethylation of H3K36
and a gain in H3K27 methylation that leads to the de-repression
and redistribution of polycomb repressive complex 1 (PRC1) asso-
ciated with a blockade of mesenchymal differentiation. K36M
mutations in H3F3B have also been detected in most chondroblas-
tomas (Behjati et al, 2013). The detection of histone mutations
could help in therapeutic choices as recently evidenced by an
instructive case of a patient diagnosed with a histiocytic neoplasm
harboring a histone H3K36I mutation. This patient did not
respond to multiple histiocytosis treatments, but showed a stable
therapeutic response after chemotherapy and radiation therapy
used for STS (Snuderl et al, 2019). Similarly, mutations in chro-
matin remodeling genes, including ATRX, DOT1L, and H3F3A,
have been identified in 14 UPS cases highlighting the potential
involvement of deregulated chromatin remodeling pathways in
tumorigenesis (Ali et al, 2019).
Epigenetic alterations and signatures have also been extensively
explored in EwS. In fact, EwS has been defined as an “enhancer
disease” with substantial levels of epigenetic heterogeneity (Toma-
zou et al, 2015; Sheffield et al, 2017). In contrast to many other
cancers, inter-tumor epigenetic heterogeneity did not uncover
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discrete subgroups in EwS, but, rather, defined a continuous spec-
trum along two distinct and biologically interpretable dimensions
(“Ewing-like” and “mesenchymal versus stem-like”; Sheffield et al,
2017). Although the clinical relevance of this epigenetic heterogene-
ity in sarcoma remains to be clarified, recent studies have high-
lighted the potential of epigenetic therapies in OS and EwS:
Selective inhibition of BET bromodomain epigenetic signaling inter-
feres with the bone-associated tumor’s vicious cycle in OS and inhi-
bits the oncogenic transcription factor EWSR1-FLI1 in EwS
(Lamoureux et al, 2014; Jacques et al, 2016; Baud’huin et al, 2017).
Super-enhancers (SEs), which are large genomic regions enriched in
active enhancers, have been identified as regulators of cellular iden-
tity (Whyte et al, 2013). In pediatric fusion-positive ARMS, PAX3-
FOXO1 was shown to establish a miswired myoblastic SE landscape,
creating a dependency on BET bromodomains (Gryder et al, 2017,
2019, 2020). BET inhibitors ablate PAX3-FOXO1 function, providing
a rationale for their use in the treatment of fusion-positive ARMS
patients (Gryder et al, 2017, 2019, 2020).
Deregulation of epigenetic programs also plays key roles in other
sarcoma subtypes, such as SS, an STS that often occurs in young
adults. The defining genetic event present in all histological variants
of SS is the translocation of the SS18 gene on chromosome 18q11 to
an SSX gene (mainly SSX1 or SSX2) located on chrXp11 (Clark et al,
1994). A recent RNA interference screen to find specific epigenetic
vulnerabilities created by the SS18-SSX oncoprotein identified a crit-
ical role for KDM2B, a member of the non-canonical polycomb
repressive complex 1 (PRC1.1) in sustaining SS cell proliferation
(Banito et al, 2018). PRC1.1 is required for the recruitment of SS18-
SSX and the mSWI/SNF complex to unmethylated CpG islands,
which enables the fusion to activate genes that would otherwise be
repressed (Banito et al, 2018). In addition, two recent studies found
a dependency of SS on the mSWI/SNF subunit BRD9 (Brien et al,
2018; Michel et al, 2018). However, further work should determine
whether these results pinpoint a requirement of BRD9 for the SS18-
SSX-driven expression program (Brien et al, 2018) and whether this
constitutes a synthetic lethal interaction by regulation of fusion-
independent genomic sites (Michel et al, 2018).
Apart from their roles in sarcomagenesis, specific epigenetic
alterations can be used to improve bone sarcoma and STS classifi-
cation, diagnosis, and patient stratification (Fig 1; Koelsche et al,
2018a; Weidema et al, 2020). The promising results of brain tumor
DNA methylation-based classification (Capper et al, 2018) fostered
adaptation of this principle to the decision-making process in
sarcoma diagnostics, which is often clinically equally challenging
(Koelsche et al, 2018a). Analyses of more than 1,000 mesenchymal
tumor samples comprising more than 50 STS and bone sarcoma
subtypes of pediatric and adult patients by array-based methylation
profiling suggested that methylation signatures can be used to accu-
rately predict sarcoma entities such as “small round blue” cell
tumors (Koelsche et al, 2018a). Furthermore, this allows for defin-
ing novel subgroups within the sarcoma subtypes, for example, in
angiosarcoma (Weidema et al, 2020). Methylation profiling also
provides evidence for defining novel entities, such as the recently
described primary intracranial sarcoma subtype with highly recur-
rent DICER1 mutations (Koelsche et al, 2018b). Thus, array-based
DNA methylation analysis will be a major step forward to quickly
and reliably discriminate between mesenchymal tumor subtypes,
thus increasing diagnostic accuracy. A free access classifier tool
currently under development will allow sarcoma subtypes to be
predicted using array-generated DNA methylation data
(www.molecularsarcomapathology.org). These molecular signa-
tures will continue to improve the knowledge and classification of
mesenchymal tumors, as well as patient outcome through more
personalized therapies.
Recent developments in functional assessment of sarcoma
biology through imaging
Imaging plays a critical role in the diagnosis, staging, and monitor-
ing of therapeutic response in sarcomas as well as in assessment of
recurrence. Routine imaging modalities include plain radiography;
despite limitations in contrast resolution, this modality is low cost,
widely available, and useful in detecting mineralization and distin-
guishing ossification from calcification for diagnostic purposes
(Kransdorf & Meis, 1993). Computed tomography (CT) is of limited
utility in evaluating STSs due to radiation concerns and poor
contrast resolution, but the ability to provide three-dimensional
information is mainly exploited to guide biopsy procedures and
detect lung metastases (Casali et al, 2018). Magnetic resonance
imaging (MRI) is the modality of choice for evaluating sarcomas,
given its excellent tissue contrast and lack of ionizing radiations,
particularly to determine tumor size and delineation of mass extent
and to identify invasion of the compartments and occasionally for
histological classification using conventional T1-weighted, T2-
weighted, and fluid-sensitive sequences (Fayad et al, 2012).
In addition to these common imaging modalities, novel tech-
niques are emerging for the functional characterization of tumors,
including metabolism and the microenvironment, and for a reliable
estimation of treatment response by complementing functional
assessments with anatomical evaluation. PET, in combination with
18F 2-fluoro-2-deoxy-D-glucose (FDG), is a valuable tool for the
characterization of cancer metabolism, since the uptake of FDG—a
non-metabolizable derivative of native glucose—correlates with the
pathological grade and can be used to discriminate between benign
lesions and STSs (Ioannidis & Lau, 2003). Moreover, it can be used
to detect metastases for the follow-up of treatments and to identify
the target regions for biopsy (Kubo et al, 2016; Harrison et al,
2017).
Magnetic resonance imaging has taken a lead in the functional
characterization of tumors, since it has the capability to provide
multiparametric analysis of biological features of sarcoma by
exploiting a variety of approaches, including chemical shift imaging
(CSI), diffusion-weighted imaging (DWI), magnetic resonance spec-
troscopy (MRS), and quantitative dynamic contrast-enhanced
(DCE)-MRI (Subhawong & Wilky, 2015). DCE-MRI provides infor-
mation on tissue vascularization, perfusion, and permeability that
can be exploited for differentiating STS from benign soft tissue
tumors (Tuncbilek et al, 2005; Pepin et al, in press), or in monitor-
ing tumor response by revealing early perfusion changes (Amit
et al, 2014; Crombé et al, 2019), or in cell proliferation assessment
(Lee et al, 2020). DWI provides measurements of tissue cellularity
and membrane integrity by assessing the Brownian motion of water
molecules in tissues. Malignant lesions are usually more cellular
than benign lesions, leading to modified Brownian motion (Amit
et al, 2014). DWI may be particularly suited for assessing treatment
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response, with an increase in water diffusion that is usually associ-
ated with a positive therapeutic response (Dudeck et al, 2008). MRS
can provide the metabolic profile of tumors and is frequently used
in sarcoma to evaluate the concentration of the membrane phospho-
lipid choline, which may serve as a marker of malignancy in muscu-
loskeletal STSs (Fayad et al, 2007, 2012). The quantitative
parameters of CSI, DWI, MRS, and DCE-MRI have also shown
promising potential as biomarkers for osseous tumors (e.g., differen-
tiation of tumor from edema, determination of biological aggressive-
ness) (Fukuda et al, 2019).
Tumor acidosis is considered a major player in promoting tumor
angiogenesis, progression, invasion, and resistance to chemo-radio-
therapy (Pillai et al, 2019). In OS, the acidic microenvironment
strongly affects the activation of MSCs by inducing clonogenicity
and invasion, in addition to promoting multidrug resistance (de-
scribed above) (Avnet et al, 2016, 2017). Indirect measurements of
acidic regions in the TME have been obtained in canine OS samples
by immunohistochemistry (IHC) analysis (Avnet et al, 2017).
Consequently, non-invasive imaging approaches are needed to
provide accurate in vivo measurements of tumor acidosis (Anemone
et al, 2019; Consolino et al, 2020). Previous MRS approaches
reported intratumoral acidosis in murine fibrosarcoma models, but
lacked the ability to assess the spatial distribution (Vaupel et al,
1989, 1994). Recently, a novel MRI-based approach has been
proposed for in vivo imaging of extracellular tumor pH with high
accuracy and spatial resolution by exploiting iopamidol, an FDA-
approved X-ray contrast medium that allows potential clinical trans-
lation (Longo et al, 2014; Anemone et al, 2019). Preclinical studies
have shown the capability of this pH mapping method to assess the
correlation between dysregulated glycolysis and tumor acidosis
(Longo et al, 2016) and monitor the treatment response to anti-
cancer therapies targeting glycolysis (Anemone et al, 2017). This
novel tumor pH imaging approach may be of particular importance
for investigating tumor acidosis in the field of sarcomas.
It is interesting to note that advances in imaging technology have
paved the way for imaging modalities that are capable of defining
drug response at earlier stages of treatment. As an example, the use
of FDG-PET after 2 weeks of treatment with pazopanib was able to
correctly classify 42% of STS patients as non-responders (Vlenterie
et al, 2019).
Novel biomarkers of sarcomas
Traditionally, histomorphological assessment of sarcoma samples in
conjunction with clinical and imaging features (See section “Recent
developments in functional assessment of sarcoma biology through
imaging”) has led to the establishment of diagnosis. In addition, the
identification of fusion gene products or overexpressed oncogenes
by IHC has enriched the clinical practice (Heymann, 2014; WHO
Classification of Tumours: Soft Tissue and Bone Tumours, 2020).
However, sarcomas often do not express specific IHC markers. In
contrast to studies on tumor biopsies, the discovery of circulating
tumor cells (CTCs), cell-free circulating tumor DNA (cfDNA), and
tumor-derived extracellular vesicles (EVs), as well as the advent of
new technologies to detect, quantify, and analyze these biological
entities in peripheral blood, hold great promise for developing mini-
mally invasive methods to improve patient care. Indeed, liquid
biopsies may enable longitudinal monitoring of treatment response,
early detection of relapse, and the identification of druggable driver
mutations. Although IHC markers remain important tools for diag-
nostics in sarcomas (as reviewed in ref. Wei et al, 2017), the aim of
this section is to focus on recent advances in the field of liquid biop-
sies in sarcoma.
Circulating cytokines as markers associated with prognosis
Deregulated levels of cytokines and their receptors can be detected
in cancer patients both locally and systemically, and they may be of
a high prognostic value in several tumor types (Kumar et al, 1998;
Belluco et al, 2000; Kawashima et al, 2000), including sarcomas.
Increased serum levels of cytokines and their soluble receptors that
are involved in bone degradation (e.g., IL-6 and IL-8) and bone
formation (e.g., tumor necrosis factor receptor I [TNFRI]) are posi-
tively correlated with tumor size and local tumor extent, which is
associated with worse overall survival in adult bone sarcoma
patients (Rutkowski et al, 2003). Several studies have recognized
the negative prognostic significance of various chemokines or
cytokines, such as CXCL4/CXCL6 (Li et al, 2011), CXCL10 (Flores
et al, 2017), IL-17A (Wang et al, 2013), IL-6, IL-8, and TNF-a (Xiao
et al, 2014) in OS patients. IL-6 levels were also elevated in serum
of a subgroup of EwS patients with poor prognosis (Lissat et al,
2015) and constitute an indicator of poor overall survival and event-
free survival in STS, suggesting a possible association with aggres-
sive tumor behavior (Hagi et al, 2017). Besides IL-6, other cytokine
signaling components including IL-8, TNF-R, sIL-2R, and M-CSF
have been shown to correlate with tumor grade and size in STS
patients, and the serum levels of some of these proteins were associ-
ated with the prognosis (Rutkowski et al, 2003). To date, the identi-
fication of specific cytokine components involved in sarcoma
progression is far from being complete, and future studies are essen-
tial for generating innovative prognostic tools and facilitating ther-
apy and risk-stratification.
Extracellular vesicles (EVs) and micro RNAs (miRNAs)
EVs are intercellular messengers where cargo (nucleic acids,
proteins, lipids, and metabolites) can be characterized and poten-
tially used as new or supplementary biomarkers in liquid biopsy
approaches (Mader & Pantel, 2017). EVs isolated from peripheral
blood samples derive not only from tumor cells but also from cells
of the TME (See section “The complex biology of sarcoma: How
current knowledge may affect therapy”). Thus, EVs can be represen-
tative of the interaction between cells in the TME and may bring
useful information to follow disease progression (Baglio et al, 2017;
Mannerström et al, 2019). One major advantage of EVs in the liquid
biopsy approaches is their membranous structure that protects their
cargo and gives them enough stability to allow EV sample storage
before analysis, which facilitates their clinical use (Jeyaram & Jay,
2017).
In 2013, Miller et al initiated the study of EVs’ diagnostic poten-
tial for sarcoma by demonstrating the efficient isolation of EVs
derived from EwS and containing EwS-specific transcripts, including
EWSR1-FLI1, in a pre-clinical model for patient plasma (Miller et al,
2013). Since then, only few clinical studies have been conducted in
limited patient cohorts exploring sarcoma-derived EVs as biomark-
ers. Circulating EV-associated transforming growth factor b (TGF-b)
levels were elevated in OS patients compared with healthy
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individuals (Baglio et al, 2017), and circulating vesicular miR-25-3p
and miR-92a-3p were elevated in LPS patients (Casadei et al, 2017).
Moreover, miR-25-3p and miR-92a-3p modulated macrophages in
the local TME, which in turn released IL-6, increasing the prolifera-
tion, migration, and invasion of cancer cells. EVs secreted by dedif-
ferentiated LPSs were also carriers of MDM2 DNA transferable to
preadipocytes, which acquired oncogenic properties (e.g., impaired
TP53) (Casadei et al, 2019). In addition, miR-642a, miR-1260b, and
miR-4286 were significantly higher in serum collected from
myxofibrosarcoma patients compared with healthy controls, and
miR-1260b expression was associated with tumor burden and the
infiltrative nature of sarcoma (Morita et al, 2020). Moreover, EVs
derived from the plasma of GIST patients expressed activated KIT,
which was undetectable in samples from healthy donors (Atay &
Godwin, 2014). Promising data were also obtained for SS, where
serum miR-92b-3p constituted a robust marker for discriminating
patients with SS from other STS patients and was elevated in EVs
compared with AGO2-positive fractions (Uotani et al, 2017). miR-
761 released in EVs enhanced pazopanib resistance in SS (Shiozawa
et al, 2018) and correlated with increased resistance. Such resis-
tance may be explained by the modulation of NAD-dependent
protein deacetylase sirtuin-3 (SIRT3) expression. Interestingly, pazo-
panib regulated the protein contents of EVs released by SS (Shio-
zawa et al, 2018), more specifically proteins from the Wnt pathway,
which is crucial for SS (Baird et al, 2005). RMS also secreted EVs,
which upregulated the proliferation of RMS cells and fibroblasts of
the TME, and initiated the migration/invasion of tumor-associated
fibroblasts through promotion of angiogenesis (Ghayad et al, 2016).
EVs secreted by cancer cells appeared as key regulators of bone
sarcoma biology. A pilot study analyzing RNA isolated from
plasma-derived EVs of OS patients found a higher tumor mutational
burden in patients with metastatic disease than in OS patients with-
out metastases (Bao et al, 2018). The response to chemotherapy can
be monitored by the identification of dysregulated levels of miRNAs
(miR-124, miR-133a, miR-135b, miR-148a, miR-199a-3p, miR-27a,
miR-385, and miR-9) and mRNAs (ANNEXIN2, CDC5L, CDKN1B,
CIP4, MTAP, PEDF, SMAD2, and WWOX) in EVs isolated from the
serum of OS patients with a poor chemotherapeutic response when
compared with good responders (Xu et al, 2017). However, before
being incorporated into routine clinical practice, a careful optimiza-
tion and standardization of EVs isolation protocols from blood
samples and validation studies in larger patient cohorts are
required. In particular, the position paper recently published by the
International Society for Extracellular Vesicles stresses the impor-
tance of a variety of critical parameters (pre-analytical parameters,
such as time to processing, type of container(s), and choice of anti-
coagulant) (Théry et al, 2018).
Circulating tumor cells (CTCs)
Circulating tumor cells are cells released from primary and meta-
static tumor foci and migrating in secondary organs through the
peripheral blood. The biological value of CTCs was assessed by
comparing the molecular profiles of CTCs and primary tumors
(Keller & Pantel, 2019). Controversial conclusions showed that CTCs
only partly reflect the spectrum of mutations in the primary and
metastatic tumors (Paoletti et al, 2018; Wu et al, 2018; Brown et al,
2019; Keller & Pantel, 2019). CTCs may be considered a snapshot of
tumor tissue heterogeneity at a given time and could have strong
implications for longitudinal patient monitoring (Brown et al, 2019;
Tellez-Gabriel et al, 2019). In contrast to studies in carcinomas
(Pantel & Alix-Panabières, 2019), studies of CTCs in sarcomas are
currently limited (Tellez-Gabriel et al, 2016). The restricted number
of patients, the high heterogeneity of sarcoma subtypes, and the
absence of specific markers expressed by most sarcoma cells contri-
bute to the limited advances in this field. Despite the absence of
specific markers, various methods of cell isolation based on physical
specificity (e.g., higher size and higher cell deformability of tumor
cells) or biological properties (e.g., immunomagnetic isolation) have
been proposed with success (Gabriel et al, 2016; Hayashi et al,
2017; Li et al, 2017). CTCs are detectable in bone sarcomas (Chinen
et al, 2014; Benini et al, 2018) and STS patients (Braun et al, 2018;
Mihály et al, 2018; Przybyl et al, 2019). To improve the sensitivity
and specificity of detection and isolation of CTCs across sarcoma
subtypes, investigators have been looking for universal sarcoma
markers (Satelli et al, 2014; Li et al, 2018). Cell-surface Vimentin
was expressed in CTCs isolated from 24 sarcoma patients compris-
ing OS, EwS, angiosarcoma, LMS, and UPS (Satelli et al, 2014).
More recently, a new class of CD45 CTCs expressing macrophage
markers CD14 and CD68, cell-surface Vimentin, and specific GIST
markers (DOG1 and KIT) have been identified (Li et al, 2018). This
CTC subset was more abundant in patients with metastatic disease
than with localized GIST. In contrast, cell-surface Vimentin-positive
cells that did not express macrophage markers failed to predict GIST
metastasis (Li et al, 2018). These studies underlined the potential
clinical interest in CTCs as prognostic or predictive markers,
although longitudinal clinical trials with a large series of patients
may be required.
Cell-free circulating tumor DNA (cfDNA)
cfDNA is composed of DNA fragments released into the bloodstream
by healthy and cancer tissues alike, as a result of cell death (e.g.,
apoptosis, necrosis) or active release (Volckmar et al, 2018; Chen &
Zhao, 2019). The cfDNA fraction released from tumor tissues, called
circulating tumor DNA (ctDNA), may reflect the genetic aberrations
of cancer cells at a given time. cfDNA was recently detected in
plasma of bone sarcoma (Gutteridge et al, 2017; Shukla et al, 2017;
Barris et al, 2018) and STS patients (Boonstra et al, 2018; Eastley
et al, 2018; Namløs et al, 2018; Ogino et al, 2018; Shulman et al,
2018). In these studies, total cfDNA levels were frequently increased
in the plasma of sarcoma patients compared with the cancer-free
controls. Cancer-associated mutations, such as in TP53, PIK3CA,
and IDH1 or fusion oncogenes (e.g., SS18-SSX1/2), were also
detected. In patients affected by GIST, mutations of KIT and
PDGFRA were detected, and the amount of mutant cfDNA correlated
with clinical progression (Maier et al, 2013). Interestingly, the
usefulness of cfDNA analysis was demonstrated to identify TKI-
resistant mutations (Yoo et al, 2014). In a series of CHSs, ctDNA
levels detected by mutated IDH1 correlated with tumor grade and
prognosis (Gutteridge et al, 2017). Patient-specific somatic alter-
ations in cfDNA were observed in OS (Barris et al, 2018) and were
associated with inferior outcomes in EwS and OS patients (Shulman
et al, 2018). Individual genomic EWSR1-ETS fusion sequences can
be quantified from cfDNA in EwS patients’ plasma, and as such
represent suitable serum markers for therapy assessment (Krumb-
holz et al, 2016). Indeed, copy numbers of cell-free EWSR1-ETS
fusion sequences correlate with patients’ risk factors such as tumor
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volume, pelvic tumor, and metastatic status, and most EwS patients
show a fast reduction of cfDNA levels during treatment, while recur-
rence of increasing cfDNA levels indicates relapse (Krumbholz et al,
2016). In addition to somatic mutations and DNA methylation,
recent studies have reported the detection of circulating nucleo-
somes in blood, showing that cfDNA retains at least some features
of nuclear chromatin. Most importantly, whole-genome sequencing
of cfDNA was shown to yield a dense, genome-wide map of nucleo-
some occupancy that enables identification of the cell types that
contribute to circulating cfDNA (Snyder et al, 2016; Ulz et al, 2016).
This is highly relevant to EwS as it supports the idea of monitoring
the chromatin state of EwS-specific enhancer elements (Riggi et al,
2014; Tomazou et al, 2015; Sheffield et al, 2017) over time and
during the treatment course, enabling the development of enhancer-
based minimally invasive assays for live monitoring of therapy
response.
Overall, the detection and characterization of cfDNA and ctDNA
in sarcomas show promising results, and efforts are now needed to
profile larger biological cohorts with complete clinical annotations
to validate their clinical value.
Recent therapeutic developments
Precision medicine in sarcoma: General considerations
The ultimate goal of personalized medicine is to be able to integrate
clinical, genomic, transcriptomic, and epigenomic data to increase
the accuracy of diagnosis and prognosis, and to identify the most
effective therapy for treatment (Burdach et al, 2018; Salgado et al,
2018; Gargallo et al, 2020). Recent advances in machine learning-
based methods for analysis of histology and radiography imaging
may also play an increasingly important role (Blackledge et al,
2019; Wang et al, 2019; Malinauskaite et al, 2020). For instance,
clinical investigations into immune checkpoint therapy have desig-
nated UPS, myxofibrosarcoma, and similar genomically complex
histotypes as “UPS” (Que et al, 2017), making comparisons with
other studies difficult. However, the inclusion of genomic analyses
led to the re-classification of 13% of sarcoma cases and would have
resulted in changes to the clinical treatment pathway or prognosis
in 11% of cases, demonstrating the importance of including molecu-
lar and computational tools for classification and risk-stratification
of sarcomas (Italiano et al, 2016).
Several recent studies have identified therapeutically targetable
mutations in sarcoma patients and have used this knowledge to
guide treatment (Groisberg et al, 2017). Yet, not all attempts were
successful (Demetri et al, 2013; Perry et al, 2014), indicating that
genomic data alone are not sufficient for the accurate prediction of
response to therapy.
The clinical trial MULTISARC (ClinicalTrials.gov No. NCT03784014)
should provide the first glimpse into the successes and potential
pitfalls of personalized medicine in sarcoma. Based on a retrospec-
tive survey of genomic alterations that could be therapeutically
actionable (Lucchesi et al, 2018), MULTISARC is a two-arm,
randomized trial aiming to prospectively evaluate their potential as
predicative biomarkers for response to therapy. STS patients will be
randomized to receive standard therapy or undergo genomic profil-
ing for suitability for therapy with 16 different agents. Sarcomas
were identified as a priority for the 100,000 genomes project in the
United Kingdom with 500 to be sequenced as part of the study,
although it will focus on LMS, myxofibrosarcoma, SS, and rare
histotypes such as alveolar soft part sarcoma (ASPS). In addition to
collecting both genomic and clinical data from patients, the project’s
Genomics England Clinical Interpretation Partnerships (GeCIPs),
including the Sarcoma GeCIP, will also identify training and stan-
dardization of practice needed to bring personalized medicine
toward routine clinical practice.
Likewise, genomic analyses in combination with screening
cancer cell lines against libraries of drugs have the potential to
improve the correlation between genomic biomarkers and response
to therapy. Such an approach has been used to identify biomarkers
for response to therapy of several sarcomas using cell lines, patient-
derived samples, and canine sarcoma as proof of principle (Berlow
et al, 2019). This approach is challenging for studying sarcoma, due
to the limited number of cell lines available, although isolation of
new cell lines (Salawu et al, 2016) and sarcoma PDX models is
improving (Stebbing et al, 2014). The next step will be to take
advantage of combining molecular information gained through
next-generation sequencing (NGS) technologies with functional drug
screening using primary organoid cultures that include both stromal
cells and cancerous cells to improve prediction of response to ther-
apy, as observed in other cancers (Tiriac et al, 2018; Vlachogiannis
et al, 2018).
Photodynamic therapy
An interesting approach, based on photo- and radiodynamic therapy
following acridine orange administration, has been extensively
investigated and successfully applied for the treatment of sarcomas
(Matsubara et al, 2013; Kusuzaki et al, 2018; Martano et al, 2019).
Photodynamic therapy with hematoporphyrin prevented local recur-
rence following minimally invasive surgery in preclinical models
(Duchi et al, 2016) as well as in clinical settings (Hourigan et al,
1993). Acridine orange has the advantage of selectively binding to
tumor tissue due to the acidic microenvironment specific to malig-
nant cells (Matsubara et al, 2006) and to specifically exert a strong
cytotoxic activity on tumor cells, which is further enhanced by
photo- and radioactivation (Matsubara et al, 2013; Kusuzaki et al,
2018). Therefore, following marginal or even intralesional gross
removal of the tumor, it is possible to selectively target residual
sarcoma and spare the surrounding normal tissues, with a satisfac-
tory functional result (Martano et al, 2019). The procedure is safe,
without local or systemic complications (Martano et al, 2019).
Systemic administration of acridine orange with low-dose radiation
therapy is currently under evaluation in Japan for non-resectable
sarcomas (Kusuzaki et al, 2018). This procedure appears to be safe,
and the preliminary results are encouraging.
Immune-based therapies
Sarcomas are highly heterogeneous, including the TME, which
might dictate their heterogeneous response to different immunother-
apeutic approaches (section “The complex biology of sarcoma: How
current knowledge may affect therapy”, Figs 2 and 3). While check-
point inhibitor immunotherapies have already been introduced for
the first-/second-line treatment of several carcinomas, their efficacy
in sarcoma treatment is currently unclear, and clinical trials are
ongoing (Thanindratarn et al, 2019). Unfortunately, the first results
showed only sporadic therapeutic responses in STSs and bone
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sarcomas, highlighting the need for further investigations (Merchant
et al, 2016).
Some STS subtypes (e.g., myxofibrosarcoma and UPS) are char-
acterized by a high mutational burden, which may constitute a
biomarker for response to immune checkpoint blockade (Pollack
et al, 2017). In addition, recent profiling studies of immune check-
points expression in STSs and bone sarcomas revealed their correla-
tion with poor clinical outcomes and provide rationales for their
targeting (Dancsok et al, 2019; Orth et al, 2020). In fact, a new
study revealed a positive correlation between immune infiltration
and response to anti-PD-L1 therapy in sarcoma (Keung et al, 2020).
Similarly, a gene expression study in 608 tumors across STS
subtypes established a classification between immune-low,
immune-high, and vascularized phenotypes (Petitprez et al, 2020).
The phenotype with the highest immune cell infiltration featured
tertiary lymphoid structures with T cells, dendritic cells, and B cells.
Interestingly, B cells were the strongest prognostic factor, and they
were associated with improved survival and high response rates to
PD-1 blockade (Petitprez et al, 2020).
Therapeutic strategies based on (genetically modified) T cells are
currently underway. Their main objectives are to enhance T-cell
infiltration into tumor tissues and identify specific tumor target anti-
gens only expressed by malignant cells (Baldauf et al, 2018b). Some
encouraging results have been described, such as the therapeutic
benefit observed in SS upon inoculation of autologous T cells engi-
neered to express an affinity-enhanced T-cell receptor (TCR) recog-
nizing the NY-ESO-1-derived peptide (D’Angelo et al, 2018).
Similarly, chimeric antigen receptor (CAR) T cells characterized by
the expression of a chimeric receptor (fusion of specific antibody-
derived single-chain variable fragments with the signaling domain
of a T-cell receptor) are capable of inducing conventional activation
signals from TCRs in a non-MHC restricted manner (Majzner &
Mackall, 2018; Pollack et al, 2018). Although some sarcomas
subtypes express tumor epitopes, such as HER2, GD2, ROR2, or
EGFRvIII, B7-H3 (Majzner et al, 2019), or oncofetal glycosaminogly-
cans (Salanti et al, 2015), these tumor epitopes are often only
expressed at low levels. CAR T cells may overcome the low levels of
tumor antigen expression, and several clinical trials are currently in
progress to evaluate their therapeutic benefit (Majzner & Mackall,
2018; Pollack et al, 2018). Interestingly, a first completed phase I/II
trial with HER2-CAR T cells showed that cells can persist for 6
weeks without evident toxicities, setting the stage for studies that
combine CAR T cells with other immunomodulatory approaches to
enhance their expansion and persistence (ClinicalTrials.gov No.
NCT00902044; Ahmed et al, 2015). OS (Théoleyre et al, 2005;
Koirala et al, 2016), EwS (Machado et al, 2018), and CHS (Simard
et al, 2017; Richert et al, 2019) are moderately infiltrated by
lymphocytes with moderate functional impact (Heymann et al,
in press). However, the number of T lymphocytes appeared to be
significantly higher in metastatic foci than in primary tumors and in
local relapses, suggesting the potential benefit of TIL-based
immunotherapy in metastatic clinical situation (Sundara et al, 2017;
Shi et al, 2020). T lymphocyte infiltration has also been described in
STS (Dancsok et al, 2019; Que et al, 2019; Shi et al, 2020). Two
phase 2 clinical trials have recently been set up for treating sarcoma
patients with autologous TIL expanded ex vivo (ClinicalTrials.gov
No. NCT03449108 & NCT03935893). Similarly, adoptive immune
cell therapy options based on infusion of NK cells were assessed in
preclinical models of bone sarcomas and STS (Thiel et al, 2013;
Fernández et al, 2015). Case reports including ERMS and EwS
showed a beneficial anti-tumor activity of allogeneic hematopoietic
stem cell transplantation (Pérez-Martı́nez et al, 2009). A pilot phase
1/2 clinical study named “NKEXPSARC” will assess the clinical
potential of activated haploidentical natural killer cell infusions in
sarcomas (ClinicalTrial.gov No. NCT02409576).
Oncolytic viruses
The approval of the Herpes virus Talimogene Laherparepvec (T-
VEC; Imlygic) by the FDA and EMA for recurrent melanoma con-
firms that virotherapy has emerged as a feasible therapeutic strategy
in oncology (Andtbacka et al, 2015; Ribas et al, 2017). Oncolytic
viruses have been assessed in bone sarcomas and STSs (Lacroix
et al, 2018; MacNeill et al, 2018; Smith et al, 2019; Tazawa et al,
2020). They are tumor selective, destroy cancer cells, and trigger an
anti-tumor immune response (Garcia-Moure et al, 2017; Varela-
Guruceaga et al, 2018). Table 2 summarizes the main potential ther-
apeutic viruses for the treatment of sarcomas.
In the group of DNA viruses, Adenovirus, Herpes virus, and
Vaccinia virus are commonly employed. These three types of viruses
have advanced to clinical trials. For example, Telomelysin, a human
telomerase reverse transcriptase (hTERT) promoter-driven modified
oncolytic Adenovirus, was tested in a phase I clinical trial to assess
its clinical safety in patients with advanced solid tumors (Nemu-
naitis et al, 2010). Herpes virus HSV1716 was tested in pediatric
patients with non-central nervous system solid tumors (ClinicalTri-
als.gov No. NCT00931931), including two patients with OS (Streby
et al, 2017). This virus was delivered as a single dose of 105–107
infectious units via CT-guided intratumoral injection, and tumor
response was measured by imaging. HSV1716 was safe in the pedi-
atric population, with minimal toxicities reported; however, no clin-
ical responses were observed in this phase I trial (Streby et al,
Table 2. Summary of main oncolytic viruses applied in sarcoma
treatment.
Virus Disease Trial
DNA
Adenovirus (Ad) Respiratory and gastrointestinal
infections
Preclinical
phase I
Herpes simplex virus
(HSV)
Oral and genital ulcerations Preclinical
phase I
Vaccinia virus Flu Preclinical
RNA
Reovirus Respiratory and gastrointestinal
infections
Preclinical
phase I
Semliki forest virus
(SFV)
Non-pathogenic in humans /
encephalitis in mice
Preclinical
Vesicular stomatitis
virus (VSV)
Non-pathogenic Preclinical
Measles virus (MeV) Measles Preclinical
Poliovirus Neurological disorders
(poliomyelitis)
Preclinical
Newcastle disease
virus (NDV
Respiratory and gastrointestinal
infections
Preclinical
phase I/II
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2017). Finally, the Vaccinia virus, armed with GM-CSF (JX-594), has
also been tested in a phase I clinical trial in pediatric solid tumors
(ClinicalTrials.gov No. NTC01169584) but did not include sarcomas.
This virus did not show toxicity, but exhibited biological activity in
the pediatric population (Cripe et al, 2015). The group of RNA
viruses, including Semliki Forest Virus, Poliovirus, Newcastle Disease
Virus, Measles, or Reovirus (Table 2), have also transitioned to clini-
cal trials (Schneider et al, 2018). However, only the Reovirus
Reolysin has been tested in OS (Kolb et al, 2015). Twenty-four
patients were treated in this trial, including OS and other extracra-
nial pediatric tumors, to establish virus safety. The virus was well
tolerated and showed a safe profile, but no response was observed
(Kolb et al, 2015).
The therapeutic effect of several oncolytic viruses in STSs (Led-
don et al, 2015; Siurala et al, 2015; Wilkinson et al, 2016; Chen
et al, 2017) and bone sarcomas (Witlox et al, 2004; Graat et al,
2006; Hingorani et al, 2014; Martı́nez-Vélez et al, 2016; Martinez-
Velez et al, 2014) was tested in various preclinical studies. Due to
their versatility and lack of toxicity, oncolytic Adenoviruses are
commonly used (Fig 4). Because the Rb pathway is frequently
mutated in sarcomas, oncolytic Adenoviruses based on selective
replication conditional to Rb pathway deregulation have been
developed. VCN-01 (Martı́nez-Vélez et al, 2016) and Delta-24-RGD
(Martinez-Velez et al, 2014) are Adenoviruses that showed in vitro
and in vivo anti-sarcoma activity. Delta-24-RGD is a replication-
competent Adenovirus that harbors a 24-bp deletion in the E1A
region (responsible for binding Rb protein) that triggers tumor
selectivity. The addition of an RGD-4C motif in the fiber H1 loop
allows enhanced infectivity through integrins that are widely
expressed in cancer cells (Suzuki et al, 2001). VCN-01 is an onco-
lytic Adenovirus where the E1A gene also contains deletions in the
pRb binding site, thus rendering its selective replication in Rb-defi-
cient tumor cells (Rodrı́guez-Garcı́a et al, 2015). Importantly, both
viruses have shown efficacy not only against the primary tumor
but also against lung metastases (Martinez-Velez et al, 2014;
Martı́nez-Vélez et al, 2016). It should be noted that most of the
oncolytic Adenoviruses are amenable to be used in combination
with standard chemotherapy, small molecules, nanoparticles,
immunotherapy with immune checkpoint inhibitors, and CAR T
cells.
Conclusions
Sarcomas comprise relatively rare but diverse cancer entities
affecting patients of all ages. Bone sarcomas are more frequent in
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Figure 4. Main features and functional aspects of oncolytic virus.
(A) Characteristics of oncolytic Adenoviruses Delta-24-RGD and VCN-01. These two Adenoviruses harbor different modifications (black for Delta-24-RG (D24-RGD) and dashed
blue for VCN-01) that render themwith tumor specificity and enhanced infectivity. (B) Schematic representation of the virus’mechanism of action. (1) The viruses are able to
infect both normal and tumor cells. (2) However, due to their tumor specificity they only replicate and lyse the tumor cells. (3) They exert a potent cytolytic effect, and they are
able to trigger an anti-tumor immune response, which is crucial to successfully eliminate the tumors.
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adolescents and young adults, and the frequency of STS increases
with age. Most sarcomas exhibit a high cellular, molecular, and
genetic/epigenetic heterogeneity, which makes identification of
single therapeutic targets more difficult. Fortunately, in some
instances, identification of new targets has revolutionized the ther-
apeutic management of sarcoma patients, as illustrated by the use
of imatinib mesylate targeting receptor tyrosine kinases in GIST
even if secondary resistance is observed (Napolitano & Vincenzi,
2019), which can be overcome with other, rationally designed TKIs
(Blay et al, 2020). The TME plays a key role in the pathogenesis of
sarcomas, not only for tumor initiation but also in the metastatic
process. Like other cancers, sarcomas are now in the era of
immunotherapy (e.g., PD-L1 inhibitors, CAR T-cell therapy) and
numerous clinical trials are currently ongoing. Epigenetic profiles
emerge as useful tools to improve diagnostic accuracy in sarcomas
and to discover or better delineate new sarcoma subtypes. In addi-
tion, epigenetic events occurring during sarcomagenesis have been
identified as new, promising opportunities for treating sarcomas.
Innate or acquired resistances of sarcomas are the principal obsta-
cles to treatment efficacy, and a better understanding of these
cellular/molecular processes will help to define better therapeutic
lines. Tackling MDR, CSCs, and/or cell dormancy are all tracks
for progress. Finally, the high heterogeneity of sarcoma requires
better classification of sarcoma subtypes based on (epi)genetic
characteristics (e.g., CTCs, circulating RNA/DNA, immune infil-
trates) to identify the best therapeutic option for each patient.
Thus, future advances in the field of molecular biology related
to sarcomas hold great promise to overcome treatment resistance
and treatment-related toxicity through individualized precision
medicine approaches.
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For more information
Societies and Network for health scientists and professionals
• EuSARC (European network for SARComa): https://eusarc.com/
• NIH website for information to health professional, related to bone cancer:
https://www.cancer.gov/types/bone/hp
• World sarcoma network: http://www.worldsarcomanetwork.
com/
Patient associations
• UK patient association on sarcoma: https://sarcoma.org.uk/about-sarcoma/
understanding-sarcoma-0
• The Liddy Shriver sarcoma initiative: http://sarcomahelp.org/sarcoma-cente
rs.html#tpm1_1
• Sarcoma patients Euronet: https://www.sarcoma-patients.eu/it/sarcoma-re
search/research-networks
OMIM site
• Ewing sarcoma: https://www.omim.org/entry/612219search=sarcoma&high
light=sarcoma
• GastroIntestinal Stromal Tumor: https://www.omim.org/entry/606764searc
h=GIST&highlight=gist
• Kaposi sarcoma: https://www.omim.org/entry/148000search=sarcoma&high
light=sarcoma
• Osteosarcoma: https://www.omim.org/entry/259500search=osteosarcoma
&highlight=osteosarcoma
• Synovial sarcoma: https://www.omim.org/entry/300813search=sarcoma
&highlight=sarcoma
Database
• Surveillance, Epidemiology, and End Results (SEER) database: https://see
r.cancer.gov/statfacts/html/bones.html
• National Program of Cancer Registries (NPCR): https://www.cdc.gov/cancer/
npcr/index.htm
• National Cancer Database (NCDB): https://www.facs.org/quality-programs/
cancer/ncdb
• ClinicalTrials.gov: https://clinicaltrials.gov/
Reference book
• WHO Classification of Tumours, 5th Edition, Volume 3. Soft Tissue and Bone
Tumours WHO Classification of Tumours Editorial Board. IARC publication
Ed. (Lyon, FR) 2020: https://www.iarc.fr/news-events/publication-of-the-
who-classification-of-tumours-5th-edition-volume-3-soft-tissue-and-bone-
tumours/
Pending issues
• Identification of unknown extrinsic factors that may have a
role in sarcoma progression and response to therapy and
that may derive from the following: (i) the tumor micro-
biome, (ii) immune infiltrates, and (iii) other cells of the
tumor-associated stroma (including neurons).
• Development of novel and more representative 3D preclini-
cal models to be used in place of animal models to develop
new therapeutic options.
• Further generation of immunocompetent and bona fide
GEMMs for all sarcoma subtypes for a better understanding
of sarcomagenesis.
• Elucidation of the mechanisms that lead to resistance
toward TKIs in non-GIST STS.
• Elaboration of non-invasive assays for the monitoring of
drug response and for early detection of drug resistance.
• Development of compounds that enhance tumor antigen
presentation and of therapeutic protocols based on
immunotherapies for the treatment of sarcoma.
• Investigation of the use of photodynamic therapies for
limb-preserving surgery.
• Optimization and clinical translation of oncolytic virus
therapies for sarcomas.
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Diagnostic sarcoma classifier
• DNA methylation-based classification: https://www.molecularsarcomapa
thology.org
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